PREFERENCES FOR ADJUVANT CHEMOTHERAPY IN AN ANZGOG SUBSTUDY OF THE PORTEC-3 INTERGROUP RANDOMIZED CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY IN HIGH RISK ENDOMETRIAL CANCER.

被引：0
|
作者：
Blinman, P. [1 ]
Mileshkin, L. [2 ]
Khaw, P. [2 ]
Goss, G. [3 ]
Johnson, C. [4 ]
Capp, A. [5 ]
Brooks, S. [6 ]
Wain, G. [7 ]
Kolodzeij, I. [8 ]
Veillard, A. S. [8 ]
Creutzberg, C. [9 ]
Stockler, M. [8 ]
机构：
[1] Concord Canc Ctr, Concord, CA USA
[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[3] Monash Med Ctr, Melbourne, Vic, Australia
[4] Wellington Hosp, Wellington, New Zealand
[5] Calvary Mater Newcastle, Auckland, New Zealand
[6] Auckland City Hosp, Auckland, New Zealand
[7] Westmead Hosp, Sydney, NSW, Australia
[8] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[9] Leiden Univ, Med Ctr, Leiden, Netherlands
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2014年 / 24卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCSM-0739
引用
收藏
页码：1482 / 1483
页数：2
相关论文
共 50 条
  • [1] Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
    Prunella Blinman
    Linda Mileshkin
    Pearly Khaw
    Geraldine Goss
    Carol Johnson
    Anne Capp
    Susan Brooks
    Gerard Wain
    Ilka Kolodziej
    Anne-Sophie Veillard
    Rachel O'Connell
    Carien L Creutzberg
    Martin R Stockler
    British Journal of Cancer, 2016, 115 : 1179 - 1185
  • [2] Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
    Blinman, Prunella
    Mileshkin, Linda
    Khaw, Pearly
    Goss, Geraldine
    Johnson, Carol
    Capp, Anne
    Brooks, Susan
    Wain, Gerard
    Kolodziej, Ilka
    Veillard, Anne-Sophie
    O'Connell, Rachel
    Creutzberg, Carien L.
    Stockler, Martin R.
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1179 - 1185
  • [3] Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy
    Creutzberg, C. L.
    Leon-Castillo, A.
    de Boer, S. M.
    Powell, M. E.
    Mileshkin, L. R.
    Mackay, H. J.
    Leary, A.
    Nijman, H. W.
    Singh, N.
    Pollock, P.
    Fyles, A.
    Haie-Meder, C.
    Smit, V. T. H. B. M.
    Edmondson, R. J.
    Putter, H.
    Kitchener, H. C.
    Crosbie, E. J.
    de Bruyn, M.
    Nout, R.
    Bosse, T.
    ANNALS OF ONCOLOGY, 2019, 30 : 899 - +
  • [4] Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer
    de Boer, Stephanie M.
    Powell, Melanie E.
    Mileshkin, Linda R.
    Katsaros, Dionyssios
    Bessette, Paul
    Haie-Meder, Christine
    Ottevanger, Petronella B.
    Ledermann, Jonathan A.
    Khaw, Pearly
    Colombo, Alessandro
    Fyles, Anthony W.
    Baron, Marie-Helene
    Kitchener, Henry C.
    Nijman, Hans
    Kruitwagen, Roy F. P. M.
    Jurgenliemk-Schulz, Ina M.
    Nout, Remi A.
    Smit, Vincent T. H. B. M.
    Putter, Hein
    Creutzberg, Carien L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Ten-year results of the PORTEC-3 trial: adjuvant therapy for women with high-risk endometrial cancer
    Post, Cathalijne C. B.
    de Boer, Stephanie M.
    Powell, Melanie E.
    Mileshkin, Linda
    Katsaros, Dionyssios
    Bessette, Paul
    Leary, Alexandra
    Ottevanger, Nelleke P.
    McCormack, Mary
    Khaw, Pearly
    D'Amico, Romerai
    Fyles, Anthony
    Chargari, Cyrus
    Kitchener, Henry C.
    Nijman, Hans W.
    Lutgens, Ludy
    Jurgenliemk-Schulz, Ina M.
    Nout, Remi A.
    Putter, Hein
    Horeweg, Nanda
    Bosse, Tjalling
    Creutzberg, Carien L.
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1122 - S1124
  • [6] Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial.
    Creutzberg, Carien L.
    de Boer, Stephanie M.
    Putter, Hein
    Powell, Melanie
    Mileshkin, Linda R.
    Katsaros, Dionyssios
    Bessette, Paul
    Haie-Meder, Christine
    Ledermann, Jonathan A.
    Ottevanger, P. B.
    Khaw, Pearly
    Colombo, Alessandro
    Fyles, Anthony W.
    Baron, Marie-Helene
    Nijman, Hans W.
    Nout, Remi A.
    Smit, Vincent T. H. B. M.
    Verhoeven-Adema, Karen
    Kruitwagen, Roy F. P. M.
    Kitchener, Henry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
    Leon-Castillo, Alicia
    de Boer, Stephanie M.
    Powell, Melanie E.
    Mileshkin, Linda R.
    Mackay, Helen J.
    Leary, Alexandra
    Nijman, Hans W.
    Singh, Naveena
    Pollock, Pamela M.
    Bessette, Paul
    Fyles, Anthony
    Haie-Meder, Christine
    Smit, Vincent T. H. B. M.
    Edmondson, Richard J.
    Putter, Hein
    Kitchener, Henry C.
    Crosbie, Emma J.
    de Bruyn, Marco
    Nout, Remi A.
    Horeweg, Nanda
    Creutzberg, Carien L.
    Bosse, Tjalling
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29) : 3388 - +
  • [8] The PORTEC-3 trial for high-risk endometrial cancer: impact of molecular classification on prognosis and benefit from adjuvant therapy
    Marnitz, Simone
    Schoemig-Markiefka, Birgid
    STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (03) : 266 - 268
  • [9] Adjuvant chemotherapy for high-risk endometrial cancer
    Pustilnik, T
    Burke, TW
    SEMINARS IN RADIATION ONCOLOGY, 2000, 10 (01) : 23 - 28
  • [10] THE ROLE OF ADJUVANT CHEMOTHERAPY IN HIGH RISK ENDOMETRIAL CANCER
    Colombo, Nicoletta
    Parma, Gabriella
    Lapresa, Maria Teresa
    Mancari, Rosanna
    Peiretti, Michele
    Sanguineti, Fabio
    Festi, Anna
    ANNALS OF ONCOLOGY, 2009, 20 : 9 - 9
12345